Extra domain B fibronectin as a target for near-infrared fluorescence imaging of rheumatoid arthritis affected joints in vivo

Molecular Imaging

Volumn 8, Issue 6, 2009, Pages 330-340

  Vollmer, Sonja ^a   Vater, Axel ^b   Licha, Kai ^b   Gemeinhardt, Ines ^b   Gemeinhardt, Ole ^b   Voigt, Jan ^b   Ebert, Bernd ^b   Schnorr, Jörg ^b   Taupitz, Matthias ^b   Macdonald, Rainer ^b   Schirner, Michael ^b  

^a BAYER PHARMA AG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE SPLICING; ANGIOGENESIS; COLLAGEN-INDUCED ARTHRITIS; CONTROL JOINT; EMBRYONIC DEVELOPMENT; EXTRACELLULAR MATRIX PROTEIN; FLUORESCENCE INTENSITIES; HUMAN ANTIBODIES; IN-VIVO; MOLECULAR IMAGING; NEAR-INFRARED DYES; NEAR-INFRARED FLUORESCENCE IMAGING; OPTICAL IMAGING; OVALBUMINS; PLANAR IMAGING; POSTINJECTION; RHEUMATOID ARTHRITIS; SINGLE-CHAIN ANTIBODIES; SYNOVIUM; TIME PERIODS; VASCULAR REMODELING;

COLLAGEN; FLUORESCENCE; HEALTH; INFRARED DEVICES; JOINTS (ANATOMY); RATS;

ANTIBODIES;

BIOLOGICAL MARKER; CARBOCYANINE; DIAGNOSTIC AGENT; ED B FIBRONECTIN PROTEIN, HUMAN; ED-B FIBRONECTIN PROTEIN, HUMAN; FIBRONECTIN; FLUORESCENT DYE; IMMUNOGLOBULIN FRAGMENT; SULFONIC ACID DERIVATIVE;

ANIMAL; ARTHRITIS; ARTICLE; CHEMISTRY; EAR; FEMALE; HINDLIMB; IMMUNOHISTOCHEMISTRY; LEWIS RAT; METABOLISM; MOUSE; NEAR INFRARED SPECTROSCOPY; RAT; SYNOVIUM; VASCULARIZATION; WHOLE BODY IMAGING;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BIOLOGICAL MARKERS; CARBOCYANINES; EAR; FEMALE; FIBRONECTINS; FLUORESCENT DYES; IMMUNOGLOBULIN FRAGMENTS; IMMUNOHISTOCHEMISTRY; MICE; RATS; RATS, INBRED LEW; SPECTROSCOPY, NEAR-INFRARED; SULFONIC ACIDS; SYNOVIAL MEMBRANE; TARSUS, ANIMAL; WHOLE BODY IMAGING;

EID: 72149106212     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2009.00030     Document Type: Article

References (51)

1. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10: 1-229, iii-iv, xi-xiii.
2. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005; 4: 130-6.
3. Venkateshan SP, Sidhu S, Malhotra S, et al. Efficacy of biologicals in the treatment of rheumatoid arthritis. A metaanalysis. Pharmacology 2009; 83: 1-9.
4. Ikeda K, Cox S, Emery P. Aspects of early arthritis. Biological therapy in early arthritis-overtreatment or the way to go? Arthritis Res Ther 2007; 9: 211.
5. Carlens C, Jacobsson L, Brandt L, et al. Perinatal characteristics, early life infections and later risk of rheumatoid arthritis and juvenile idiopathic arthritis. Ann Rheum Dis 2009; 68: 1159-64.
6. Chang M, Rowland CM, Garcia VE, et al. A large-scale rheumatoid arthritis genetic study identifies association at chromosome 9q33.2. PLoS Genet 2008; 4: e1000107.
7. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009; 11: Suppl 1: S1.
8. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
9. Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 2004; 63: 627-33.
10. McQueen FM, Ostergaard M. Established rheumatoid arthritis-new imaging modalities. Best Pract Res Clin Rheumatol 2007; 21: 841-56.
11. Xanthopoulos E, Hutchinson CE, Adams JE, et al. Improved wrist pannus volume measurement from contrast-enhanced MRI in rheumatoid arthritis using shuffl e transform. Magn Reson Imaging 2007; 25: 110-6.
12. Taylor PC. The value of sensitive imaging modalities in rheumatoid arthritis. Arthritis Res Ther 2003; 5: 210-3.
13. Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res 2004; 64: 8009-14.
14. Klohs J, Wunder A, Licha K. Near-infrared fluorescent probes for imaging vascular pathophysiology. Basic Res Cardiol 2008; 103: 144-51.
15. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003; 9: 123-8.
16. Ebert B, Sukowski U, Grosenick D, et al. Near-infrared fluorescent dyes for enhanced contrast in optical mammography: phantom experiments. J Biomed Opt 2001; 6: 134-40.
17. Schirner M, Menrad A, Stephens A, et al. Molecular imaging of tumor angiogenesis. Ann N Y Acad Sci 2004; 1014: 67-75.
18. Hansch A, Sauner D, Hilger I, et al. Noninvasive diagnosis of arthritis by autofluorescence. Invest Radiol 2003; 38: 578-83.
19. Scheel AK, Krause A, Rheinbaben IM, et al. Assessment of proximal finger joint inflammation in patients with rheumatoid arthritis, using a novel laser-based imaging technique. Arthritis Rheum 2002; 46: 1177-84.
20. Prapavat V, Runge W, Mans J, et al. [The development of a finger joint phantom for the optical simulation of early infl ammatory rheumatic changes]. Biomed Tech (Berl) 1997; 42: 319-26.
21. Hansch A, Frey O, Hilger I, et al. Diagnosis of arthritis using near-infrared fl uorochrome Cy5.5. Invest Radiol 2004; 39: 626-32.
22. Fischer T, Gemeinhardt I, Wagner S, et al. Assessment of unspecific near-infrared dyes in laser-induced fluorescence imaging of experimental arthritis. Acad Radiol 2006; 13: 4-13.
23. Wunder A, Tung CH, Muller-Ladner U, et al. In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. Arthritis Rheum 2004; 50: 2459-65.
24. Wunder A, Schellenberger E, Mahmood U, et al. Methotrexateinduced accumulation of fluorescent annexin V in collageninduced arthritis. Mol Imaging 2005; 4: 1-6.
25. Chen WT, Mahmood U, Weissleder R, et al. Arthritis imaging using a near-infrared fluorescence folate-targeted probe. Arthritis Res Ther 2005; 7: R310-7.
26. Hansch A, Frey O, Sauner D, et al. In vivo imaging of experimental arthritis with near-infrared fluorescence. Arthritis Rheum 2004; 50: 961-7.
27. Lainer DT, Brahn E. New antiangiogenic strategies for the treatment of proliferative synovitis. Expert Opin Investig Drugs 2005; 14: 1-17.
28. Ebbinghaus C, Scheuermann J, Neri D, et al. Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curr Pharm Des 2004; 10: 1537-49.
29. Zardi L, Carnemolla B, Siri A, et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. Embo J 1987; 6: 2337-42.
30. Borsi L, Allemanni G, Castellani P, et al. Structural differences in the cell binding region of human fibronectin molecules isolated from cultured normal and tumor-derived human cells. FEBS Lett 1985; 192: 71-4.
31. Berndt A, Borsi L, Luo X, et al. Evidence of ED-B+ fibronectin synthesis in human tissues by non-radioactive RNA in situ hybridization. Investigations on carcinoma (oral squamous cell and breast carcinoma), chronic inflammation (rheumatoid synovitis) and fi bromatosis (Morbus Dupuytren). Histochem Cell Biol 1998; 109: 249-55.
32. Kriegsmann J, Berndt A, Hansen T, et al. Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Rheumatol Int 2004; 24: 25-33.
33. Dietrich T, Perlitz C, Licha K, et al. ED-B fibronectin (ED-B) can be targeted using a novel single chain antibody conjugate and is associated with macrophage accumulation in atherosclerotic lesions. Basic Res Cardiol 2007; 102: 298-307.
34. Pini A, Viti F, Santucci A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a twodimensional gel. J Biol Chem 1998; 273: 21769-76.
35. Berndorff D, Borkowski S, Moosmayer D, et al. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med 2006; 47: 1707-16.
36. Berndorff D, Borkowski S, Sieger S, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: Identification of the best-suited radioimmunoconjugate. Clin Cancer Res 2005; 11: 7053s-63s.
37. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med 1977; 146: 857-68.
38. Durie FH, Fava RA, Noelle RJ. Collagen-induced arthritis as a model of rheumatoid arthritis. Clin Immunol Immunopathol 1994; 73: 11-8.
39. Holmdahl R, Lorentzen JC, Lu S, et al. Arthritis induced in rats with nonimmunogenic adjuvants as models for rheumatoid arthritis. Immunol Rev 2001; 184: 184-202.
40. Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol 2003; 25: 3-18.
41. Krenn V, Morawietz L, Haupl T, et al. Grading of chronic synovitis-a histopathological grading system for molecular and diagnostic pathology. Pathol Res Pract 2002; 198: 317-25.
42. Levick JR. Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum 1981; 24: 1550-60.
43. Wunder A, Muller-Ladner U, Stelzer EH, et al. Albuminbased drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 2003; 170: 4793-801.
44. Saborowski O, Simon GH, Raatschen HJ, et al. MR imaging of antigen-induced arthritis with a new, folate receptortargeted contrast agent. Contrast Media Mol Imaging 2007; 2: 72-81.
45. Lipsky PE. Why does rheumatoid arthritis involve the joints? N Engl J Med 2007; 356: 2419-20.
46. Mayer-Kuckuk P, Boskey AL. Molecular imaging promotes progress in orthopedic research. Bone 2006; 39: 965-77.
47. Molenaar ET, Voskuyl AE, Dinant HJ, et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004; 50: 36-42.
48. Kirwan JR. The synovium in rheumatoid arthritis: evidence for (at least) two pathologies. Arthritis Rheum 2004; 50: 1-4.
49. Maurer B, Distler JH, Moritz F, et al. [Angiogenesis. Possibilities for therapeutic intervention in rheumatic diseases]. Z Rheumatol 2007; 66: 304, 6-10.
50. Firestein GS. Biomedicine. Every joint has a silver lining. Science 2007; 315: 952-3.
51. Gomez-Puerta JA, Sanmarti R, Rodriguez-Cros JR, et al. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann Rheum Dis 2004; 63: 896. (Pubitemid 38850474)